353
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacokinetic and pharmacodynamic evaluation of sublingual sufentanil in the treatment of post-operative pain

&
Pages 217-224 | Received 07 Aug 2015, Accepted 16 Dec 2015, Published online: 22 Jan 2016
 

ABSTRACT

Introduction: Intravenous patient-controlled analgesia using opioids is frequently used to provide perioperative analgesia. However, there are a number of drawbacks for intravenous patient-controlled analgesia. The sufentanil sublingual tablet system is a major evolution in technology and drug development for postoperative pain management.

Areas Covered: We reviewed the use of sublingual sufentanil in postoperative pain management, with a focus on chemistry, pharmacokinetics and clinical use in different surgical patients.

Expert Opinion: The sufentanil sublingual tablet system can decrease intravenous patient-controlled analgesia-related safety issues. Current clinical studies have demonstrated this novel system to be safe and effective in postoperative pain management.

Declaration of Interest

R Babazade is supported by Tubitak. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed

Box 1 Drug summary.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.